Tomi K. Sawyer - Concepedia

Author

Tomi K. Sawyer

Also Known As

Christine Humblet, Sawyer, Tomi, T K Sawyer, T Sawyer, T. K. SAWYER, T. K. Sawyer, T. Sawyer, T.K Sawyer, T.K. SAWYER, T.K. Sawyer

279

Publications

10.2K

Citations

H-Index

125

Concepts

All Affiliations

University of Arizona Ariadne Diagnostics (United States)W.E. Upjohn Institute for Employment Research Merck & Co., Inc., Rahway, NJ, USA (United States)Pfizer (United States)

About

Tomi K. Sawyer is an author at University of Arizona specializing in medicine, pharmacology, and biochemistry.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	33	66	5.1K
2	Natural Sciences	25	39	2K
3	Engineering	6	6	280
4	Health Sciences	1	1	108
5	Social Sciences	1	1	36

Tomi K. Sawyer

114

Publications

9.1K

Citations

H-Index

Page 1

	Year	Citations
AP24534, a Pan-BCR-ABL Inhibitor for Chronic Myeloid Leukemia, Potently Inhibits the T315I Mutant and Overcomes Mutation-Based Resistance Thomas O’Hare, William C. Shakespeare, Xiaotian Zhu, Cancer Cell Hematological MalignancyTumor BiologyChronic Myeloid LeukemiaOncologyPan-bcr-abl Inhibitor	2009	1.2K
Stapled α−helical peptide drug development: A potent dual inhibitor of MDM2 and MDMX for p53-dependent cancer therapy Yong S. Chang, Bradford Graves, Vincent Guerlavais, Proceedings of the National Academy of Sciences	2013	653
4-Norleucine, 7-D-phenylalanine-alpha-melanocyte-stimulating hormone: a highly potent alpha-melanotropin with ultralong biological activity. Tomi K. Sawyer, Pauline J. Sanfilippo, Victor J. Hruby, Proceedings of the National Academy of Sciences Frog Skin BioassayBiochemistryEndocrine MechanismMedicinePotent Alpha-melanotropin	1980	576
Probing the α‐Helical Structural Stability of Stapled p53 Peptides: Molecular Dynamics Simulations and Analysis Zuojun Guo, Udayan Mohanty, Justin Noehre, Chemical Biology & Drug Design	2010	387
Discovery of 3-[2-(Imidazo[1,2-<i>b</i>]pyridazin-3-yl)ethynyl]-4-methyl-<i>N</i>-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide (AP24534), a Potent, Orally Active Pan-Inhibitor of Breakpoint Cluster Region-Abelson (BCR-ABL) Kinase Including the T315I Gatekeeper Mutant Wei‐Sheng Huang, Chester A. Metcalf, Raji Sundaramoorthi, Journal of Medicinal Chemistry Drug TargetImmunologyMolecular BiologyT315i Gatekeeper MutantNative Bcr-abl	2010	357
.alpha.-Melanotropin: the minimal active sequence in the frog skin bioassay Victor J. Hruby, Brian C. Wilkes, Mac E. Hadley, Journal of Medicinal Chemistry	1987	274
Structure at 2.5-.ANG. resolution of chemically synthesized Human Immunodeficiency Virus Type 1 protease complexed with a hydroxyethylene-based inhibitor Mariusz Jaskólski, Alfredo G. Tomasselli, Tomi K. Sawyer, Biochemistry	1991	229
Identification of Src-Specific Phosphorylation Site on Focal Adhesion Kinase: Dissection of the Role of Src SH2 and Catalytic Functions and Their Consequences for Tumor Cell Behavior Valerie G. Brunton, Egle Avizienyte, Valerie J. Fincham, Cancer Research Cell AdhesionMolecular BiologyCytoskeletonSrc Sh2Cancer Biology	2005	209
Inhibition of wild-type and mutant Bcr-Abl by AP23464, a potent ATP-based oncogenic protein kinase inhibitor: implications for CML Thomas O’Hare, Roy M. Pollock, Eric P. Stoffregen, Blood	2004	198
Substrate specificity of the protein tyrosine phosphatases. Z.Y. Zhang, Andrea M. Thieme-Sefler, Derek Maclean, Proceedings of the National Academy of Sciences Protein FunctionSignal TransductionBiochemistrySingular Ala SubstitutionNatural Sciences	1993	192

Page 1